Banking immune cells from recovered COVID-19 patients
Human Leucocytes Bank From COVID-19 Cured Patients With a Cellular Immunity Against SARS-CoV-2 :Raw Material for the Preparation of an Anti-SARS-CoV-2 Cellular Immunotherapy
This study is trying to see if immune cells from people who recovered from COVID-19 can be stored and used to help treat others with severe COVID-19.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 32 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Vandœuvre-lès-Nancy, Lorraine) |
| Trial ID | NCT05458440 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a biobank for preserving and producing cellular immunotherapy using T lymphocytes from convalescent COVID-19 donors. Patients hospitalized for COVID-19 at the University Hospital of Nancy will be approached for participation after recovery, specifically those with demonstrated cellular immunity against SARS-CoV-2. Blood samples will be collected and tested for various infectious markers to ensure safety before banking the immune cells. The goal is to explore the feasibility of using these cells to improve outcomes for patients with severe COVID-19.
Who should consider this trial
Good fit: Ideal candidates are hospitalized COVID-19 patients who have recovered and show active cellular immunity against SARS-CoV-2.
Not a fit: Patients with severe comorbidities, active infections, or those hospitalized in intensive care will not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to new immunotherapies that enhance recovery for patients suffering from severe COVID-19.
How similar studies have performed: Other studies have explored the use of convalescent plasma and T cell therapies for COVID-19, showing promising results, but this specific approach is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient hospitalised for proved SARS-CoV-2 infection in the infectious disease unit of the Nancy University Hospital who received a comprehensive information about the study, and accepted to participate * Patient who has an active cellular immunity against SARS-CoV-2 (biological definition: Elispot IFNgamma : \> 50 SFC/106 PBMC) Exclusion Criteria: * Patient hospitalised in Intensive car unit * Patient with haemoglobin \< 10 g/dl * Patient who take hypertension medication * Patient with cardiovascular history: Valvulopathy, conduction rythm disorders, arterial vascular insufficiency, congenital anomalies * Patient with auto-immune disease * Patient with medical history of solid or hematopoietic graft * Patient with active malignant disease (haematological or neoplasm) or considered in remission since less than 2 years * Patient with psychiatric disorders * Patient subject to a legal protection measure. * Patient with proved infectious disease * Asplenic patient * Pregnant or breastfeeding woman * Woman without contraception
Where this trial is running
Vandœuvre-lès-Nancy, Lorraine
- CHRU-Nancy - Hopitaux de Brabois - Batiment Philippe Canton — Vandœuvre-lès-Nancy, Lorraine, France (Recruiting)
Study contacts
- Study coordinator: Benjamin Lefèvre
- Email: b.lefevre@chru-nancy.fr
- Phone: +33383157654
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.